Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.
Health Catalyst (HCAT)
Consensus Price Target: $3.88 (85% implied return)
Built on its "Health Catalyst Flywheel" methodology that emphasizes measurable outcomes, Health Catalyst (NASDAQ: HCAT) provides data and analytics technology and services that help healthcare organizations manage their data and drive measurable clinical, financial, and operational improvements.
Why Do We Avoid HCAT?
- Muted 4.4% annual revenue growth over the last two years shows its demand lagged behind its software peers
- Long payback periods on sales and marketing expenses limit customer growth and signal the company operates in a highly competitive environment
- Cash-burning history makes us doubt the long-term viability of its business model
Health Catalyst’s stock price of $2.10 implies a valuation ratio of 0.5x forward price-to-sales. If you’re considering HCAT for your portfolio, see our FREE research report to learn more.
BlackLine (BL)
Consensus Price Target: $60.46 (42.6% implied return)
Born from the vision to eliminate tedious manual spreadsheet work for accountants, BlackLine (NASDAQ: BL) provides cloud-based software that automates and streamlines financial close, intercompany accounting, and invoice-to-cash processes for accounting departments.
Why Is BL Not Exciting?
- Offerings struggled to generate meaningful interest as its average billings growth of 7.2% over the last year did not impress
- Customers generally do not adopt complementary products as its 103% net revenue retention rate lags behind the industry standard
- Static operating margin over the last year shows it couldn’t become more efficient
At $42.41 per share, BlackLine trades at 3.8x forward price-to-sales. Dive into our free research report to see why there are better opportunities than BL.
Penguin Solutions (PENG)
Consensus Price Target: $26.88 (54.1% implied return)
Based in the US, Penguin Solutions (NASDAQ: PENG) is a diversified semiconductor company offering memory, digital, and LED products.
Why Do We Think PENG Will Underperform?
- Annual revenue growth of 3.7% over the last five years was below our standards for the semiconductor sector
- Competitive supply chain dynamics and steep production costs are reflected in its low gross margin of 28.8%
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
Penguin Solutions is trading at $17.44 per share, or 8.6x forward P/E. To fully understand why you should be careful with PENG, check out our full research report (it’s free).
Stocks We Like More
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
